THE AZELAPRAG CLINICAL TRIALS DIARIES

The choice follows observations of liver transaminitis devoid of clinically significant signs or symptoms, and without distinct dose dependence, in some individuals while in the azelaprag arms with the STRIDES Period 2 clinical demo for being overweight (connection).Strong cytochrome P450 3A4 and/or P-glycoprotein inhibitors may perhaps warrant AMG